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RESEARCH ARTICLE
CD5 expression promotes IL-10 production through
activation of the MAPK/Erk pathway and upregulation of
TRPC1 channels in B lymphocytes
Soizic Garaud1,9, Taher E Taher2,9, Marjolaine Debant1, Miguel Burgos3, Sarra Melayah1,
Christian Berthou1, Kaushal Parikh4, Jacques-Olivier Pers1, Damien Luque-Paz1,5, Gilles Chiocchia6,
Maikel Peppelenbosch7, David A Isenberg8, Pierre Youinou1, Olivier Mignen3, Yves Renaudineau1,5,10
and Rizgar A Mageed2,10
CD5 is constitutively expressed on T cells and a subset of mature normal and leukemic B cells in patients with
chronic lymphocytic leukemia (CLL). Important functional properties are associated with CD5 expression in B cells,
including signal transducer and activator of transcription 3 activation, IL-10 production and the promotion of
B-lymphocyte survival and transformation. However, the pathway(s) by which CD5 inﬂuences the biology of B cells
and its dependence on B-cell receptor (BCR) co-signaling remain unknown. In this study, we show that CD5
expression activates a number of important signaling pathways, including Erk1/2, leading to IL-10 production
through a novel pathway independent of BCR engagement. This pathway is dependent on extracellular calcium
(Ca2+) entry facilitated by upregulation of the transient receptor potential channel 1 (TRPC1) protein. We also show
that Erk1/2 activation in a subgroup of CLL patients is associated with TRPC1 overexpression. In this subgroup of
CLL patients, small inhibitory RNA (siRNA) for CD5 reduces TRPC1 expression. Furthermore, siRNAs for CD5 or for
TRPC1 inhibit IL-10 production. These ﬁndings provide new insights into the role of CD5 in B-cell biology in health
and disease and could pave the way for new treatment strategies for patients with B-CLL.
Cellular & Molecular Immunology (2016) 13, 1–13. doi:10.1038/cmi.2016.42; published online xx xxx 2016
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INTRODUCTION
CD5 is expressed on T cells and a subpopulation of B cells,
speciﬁcally B1 cells.1 B1 cells comprise a large subset of B
lineage cells during early life, but their frequency among total B
cells declines with age.2 The B1 subset has important roles
in the immune system, produces natural antibodies and
contributes to innate immunity. However, these cells can also
give rise to leukemic B cells in patients with chronic
lymphocytic leukemia (CLL).3 The involvement of CD5 in
the pathophysiology of B-CLL has yet to be conclusively
established, but there is evidence that CD5 is involved in
B-CLL development, at minimum through the production of
IL-10.4 CD5+ B cells produce IL-10 and are the main B-cell
source of this cytokine.5 This ability is relevant to B-CLL
pathophysiology because IL-10 acts as a growth factor for B
cells via its stimulatory6,7 and anti-apoptotic properties.8
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Furthermore, IL-10 production is associated with the outcome
of CLL9 and with a malignant genotype.10
Recently, we revealed that CD5 induces IL-10 production by
activating signal transducer and activator of transcription 3
(STAT3) and nuclear factor of activated T cells 2 (NFAT2) in a
subset of B-CLL cells.11,12 Interestingly, the activation of these
transcription factors inﬂuences disease progression in patients
with B-CLL.13,14
CD5 is a member of the conserved scavenger receptor
cysteine-rich superfamily.15 It has a cytoplasmic tail that exerts
no enzymatic activity but contains a conserved motif with a
threonine and four tyrosine residues. Two of these tyrosines
(Y429 and Y441) serve as docking sites for phosphorylated Src
homology 2 (SH2) domain-containing proteins.16 In T and B
lymphocytes, CD5 associates with Src kinases such as Lyn,
which phosphorylates the SH2 domain of CD5, creating
docking sites for Lck, Zap70, PI3K, c-Cbl and the SH2/SH3
RasGap.17,18 In contrast, the phosphatase SHP1 binds CD5 on
Y378.19 In a yeast two-hybrid system, CD5 was found to
associate with CAM kinase IIδ and casein kinase II (CK2),
which phosphorylate CD5 serine 459 (Ser459) and serine 461
(Ser461), respectively.20,21 CD5+ B lymphocytes exhibit delayed
JNK activation and lack the ability to induce p38 MAPK and
NF-κB activation upon B-cell receptor (BCR) crosslinking,
although Erk1/2 and NFAT2 are constitutively active.22
Furthermore, CD5 reduces intracellular Ca2+ mobilization
upon BCR engagement.23 On the basis of these ﬁndings,
CD5 has been implicated in B-lymphocyte tolerance and
leukemic transformation.24
In this study, we report changes in multiple intra-
cellular signaling pathways resulting from CD5 expression.
CD5 promotes constitutive MAPK activation through a
Ca2+-dependent pathway, leading to Erk1/2 phosphorylation
(pErk1/2) and IL-10 production. This IL-10 production is
independent of BCR engagement but is associated with the
expression of a non-selective channel permeable to Ca2+,
transient receptor potential channel 1 (TRPC1). In addition,
CD5 promotes the activation of the PI3K/Akt/mTOR pathway,
which has important roles in B-cell survival and proliferation.
These effects occur through the ability of CD5 to activate a
range of key kinases.25 Furthermore, we show that in pErk1/2-
positive CLL B cells, small interfering RNA (siRNA) against
CD5 suppresses TRPC1 expression, while siRNAs against CD5
or TRPC1 inhibit IL-10 production.
MATERIALS AND METHODS
Patients
Twenty-six patients who fulﬁlled the criteria for CLL26 were
recruited at the Centre of Ressources Biologiques-santé in Brest
(Table 1). Disease assessment included Binet stage determina-
tion, progression-free survival, CD38 expression, cytogenetic
abnormalities and lymphocyte counts. Informed consent was
obtained from all patients, and the Ethical Committee at Brest
University Medical School Hospital approved the study. B cells
were enriched to 496% using an enrichment kit (StemCell
Technologies, Cambridge, UK).
Cell culture
The CD5-negative hairy B-cell leukemia cell line Jok-1,27 which
possesses the phenotypic characteristics of B-CLL cells,28 was
transfected with cDNA for either the membrane isoform
of CD5, E1A (Jok-E1A) or the cytoplasmic E1B isoform
(Jok-E1B).11 Cells were maintained in RPMI-1640 containing
10% fetal calf serum, antibiotics and 0.5 mg/ml G418
(Sigma-Aldrich, Dorset, UK). For activation, 106 cells/ml were
stimulated with 10 μg/ml goat F(ab’)2 anti-human IgM coated
onto Sepharose beads (Bio-Rad, Hemel Hempstead, UK). For
inhibition experiments, 106 cells/ml were incubated for 48 h
with 50–100 μM PD98059 (inhibits Mek1; Calbiochem,
Watford, UK), 100 μM lanthanum (La3+; blocks extracellular
Ca2+ entry; Sigma-Aldrich) or 50 μM LY294002 (inhibits PI3K;
Sigma-Aldrich) and 10 ng/ml rapamycin (inhibits mTOR;
Pﬁzer, New York, NY, USA). IL-10 levels in culture super-
natants were quantiﬁed using ELISA (BD OptiEIA; BD
Biosciences, Oxford, UK).
Antibodies
Antibodies (Abs) to Erk1/2, phosphorylated-Erk1/2 (pErk1/2),
Syk/pSyk, Btk/pBtk, PLCγ2/pPLCγ2, SHP1/pSHP1, SHIP/
pSHIP were obtained from Insight Biotechnology (Middlesex,
UK). Abs to Lyn, c-Cbl, Vav1, CD79a, S6K/pS6K T389,
STAT3/pSTAT3 S727, STAT1/pSTAT1 S727, Akt/pAkt S473
were obtained from Abcam (Cambridge, UK). The anti-CD5
clone UCHT2, the rabbit anti-extracellular TRPC1, and the
mouse anti-β-actin Abs were obtained from BD Biosciences
and Sigma-Aldrich, respectively.
Western blotting and immunoprecipitation
Cell lysates in 1% NP-40 buffer (1% NP-40, 150mM NaCl,
2 mM EDTA, 10mM Tris-HCl at pH 7.4, 5 mM sodium
ﬂuoride) containing protease/phosphatase inhibitors were
separated using 10% SDS–polyacrylamide gel electrophoresis,
blotted onto polyvinylidene ﬂuoride membranes, probed
with Abs and visualized with horseradish peroxidase-
conjugated secondary Abs and enhanced chemiluminescence
(Amersham-Pharmacia, Little Chalfont, UK). For immunopre-
cipitation, lysates were cleared using centrifugation, incubated
with Abs coupled to protein G-Sepharose, washed and analyzed
using western blotting (WB).
Flow cytometry
Expression of TRPC1 was detected with speciﬁc rabbit Abs
followed by incubation with ﬂuorescein isothiocyanate-
conjugated goat (Fab’)2 anti-rabbit IgG (ImmunoResearch,
Newmarket, UK). Data were acquired and analyzed using an
FC500 ﬂow cytometer (Beckman-Coulter, High Wycombe,
UK) relative to staining with the isotype control. The results
were expressed as the mean ﬂuorescence intensity (MFI).
Measurement of intracellular calcium (iCa2+) levels
Imaging was performed to monitor iCa2+ mobilization in B
cells loaded for 30min at 37 °C with 2 μM Fura-2/AM. B cells
in six independent experiments were washed and attached
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onto cell-Taq pre-coated coverslips. Fura-2-ﬂuorescence was
excited sequentially at 340 and 380 nm, emission recorded at
520 nm and excitation/emission ratios calculated. Extracellular
Ca2+ depletion was monitored to measure iCa2+ release.
Repletion with 1.8 mM Ca2+ was used to evaluate Ca2+ entry,
and subsequent addition of 100 μM La3+ was used to block
entry. In selected experiments, ratios were normalized to basal
values (F0) at the beginning of each experiment and are
provided as (ΔF/F0).
Transfection with small interfering RNA (siRNA)
A total of 106 cells were transfected with siRNA at 3 pM using a
B-cell Nucleofector Transfection Kit (Lonza, Amboise, France).
siRNAs complementary to CD5 RNA plus control siRNA were
purchased from Ambion (Life Technologies, Paisley, UK).
siRNAs complementary to TRPC1 (3′-GCAUCGUAUUUCA
CAUU CU-3′; 5′-UGAGCCUCUUGACAAACGA-3′) were
obtained from Eurogentec (Seraing, Belgium).
Kinome array analysis
A kinome array (Pepscan Systems, Lelystad, The Netherlands)
was performed as previously described.25 Brieﬂy, 106 Jok-1,
Jok-E1A or Jok-E1B cells were lysed in 50 μl lysis buffer and
analyzed. The array comprises 1024 peptides representing
phosphorylation sites in protein substrates of all known kinases
spotted onto glass slides. Ten microliters of the peptide array
incubation mix (50% glycerol, 50 μM ATP, 0.05% v/v Brij-35,
0.25mg/ml bovine serum albumin, [33P] ATP (1MBq)) was
added to each of the lysates, and the samples were loaded onto
the chips and permitted to phosphorylate for 90 min at 37 °C.
Washed and dried slides were exposed using a phosphorimager
for 72 h, and data were acquired (Storm, Amersham-
Biosciences). The levels of incorporated radioactivity, which
correspond to phosphorylation levels, were quantiﬁed using the
array software Scanalyze (Eisen Software, Toronto, ON,
Canada). Differential kinase activation in Jok-E1A and Jok-
E1B cells was quantiﬁed and represented as signiﬁcant fold
changes in the ratio of phosphorylated peptides compared with
untransfected Jok-1 cells. All analyses were carried out in
triplicate and repeated on two separate occasions.
Construction of CD5 mutants
Two deletion mutants, S398Mstart and S415Mstart, and three
proteins with amino acid replacements were generated. The
extracellular domains and transmembrane (Tm) regions in
both deletion mutants were deleted. The SHP-1 and the
CaM-binding motifs were removed from the S398Mstart
Table 1 Demographic, clinical and immunological information on patients with CLL included in the study
CLL Age years Sex Binet Follow-up
(years)
PFS (months) Ly (×109/l) CD19+ CD5+
CD38+ (%)
Cytogenetic pErk1/2 statusa
1 53 F B 4 36 38,2 1 del13q14 neg
2 55 M A 10 4120 41,7 0 del13q14 neg
3 65 M C 2 26 42,1 88 del13q14 neg
4 86 F A 7 484 23,9 2 del13q14 neg
5 73 M A 8 102 38,2 7 del13q14 neg
6 74 M B 6 57 25,8 2 del13q14 neg
7 67 F A 5 460 14,3 4 normal neg
8 63 M B 1 10 56 30 del11q/ATM, del 13q14 neg
9 65 F B 3 18 20.6 0 del13q14 neg
10 85 M A 9 4108 35,6 8 normal neg
11 53 F A 8 496 26,8 0 del13q14 neg
12 67 F A 4 454 9,5 64 trisomy 12 neg
13 77 F A 6 477 20,4 0 del13q14 neg
14 88 F A 20 4240 19,8 7 ND pos
15 77 M B 16 126 96 50 del13q14 pos
16 71 M B 7 72 69,2 20 trisomy 12, del13q14 pos
17 83 M A 5 65 57,8 11 del13q14 pos
18 76 M A 10 4120 31,3 7 del13q14 pos
19 79 M A 2 424 14,9 4 ND pos
20 74 F B 10 123 45,7 7 del13q14 pos
21 74 F A 5 457 41.8 48 del13q14 neg
22 77 M A 3 436 16.7 26 normal pos
23 66 M A 12 4130 62.5 0 del13q14 neg
24 63 F B 9 90 60.4 8 del13q14 neg
25 84 F B 5 46 61.9 23 del17p/TP53, del13q14 pos
26 56 F B 7 36 35.3 1 del13q14 pos
Abbreviation: CLL, chronic lymphocytic leukemia; Ly, lymphocytes numbers; ND, not determined; neg, negative; PFS: progression-free survival; pos, positive.
aIndicates CLL patient divided on the basis of the phosphorylation status of MAPK Erk1/2 in their B cells into neg (pErk1/2−); pos (pErk1/2+).
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mutant in addition to the ﬁrst CK2 motif from the S415Mstart
mutant. These mutants were generated using PCR using
ATG-containing sense/antisense primers, cloned into the
pDNR-dual plasmid and subcloned into the pLPcmv vector
using the Cre-recombinase system (BD Biosciences). The E1A-
CD5 cDNA was mutated at three amino acid positions using
the Quick-Change Site-Directed Mutagenesis Kit (Agilent
Technologies, Les Ulis, France). Point mutations were intro-
duced into the serine phosphorylation sites (422AS423→ 422
VD423; 428EYS430→ 428AAA430; 459SDS461→ 459VDG461). All
constructs were validated using sequencing.
cDNA microarray
cDNA microarray analysis was performed according to Agilent
Technologies’ instructions as described.29 Thirteen micrograms
of mRNA were reverse-transcribed and ﬂuorescence-labeled
using the cyanine 3-CTP-RNA Quick Ampliﬁcation Kit.
Labeled cDNAs were hybridized to the Agilent Whole Human
Genome Oligo Microarray (4 × 44 k). Each sample was hybri-
dized with three arrays as biological replicates, the slides were
washed and dried and the ﬂuorescence was quantiﬁed with a
scanner (Agilent-G2565AA). The signals were analyzed after
subtracting background outliers using the Feature Extraction
Software (Les Ulis, France). Signal values were calculated as the
ratios between the signal intensities from the Jok-E1A or Jok-
E1B cells to the Jok-1 cells. The data can be viewed in the
National Center for Biotechnology Information (NCBI) Gene
Expression Omnibus (GEO) database (accession number
GSE50714). Data normalization, quality control and probe list
processing were all carried out with GeneSpring GX using the
Agilent Feature Extractor plug-in.29
RT-PCR and quantitative RT-PCR
RNA was extracted using the RNeasy kit (Qiagen, Les Ulis,
France) and reverse-transcribed using oligo-dT. RT-PCR was
used to amplify CD5 (sense: 5′-TCGGACGGCTCAGCTGGT
ATGAC-3′; antisense: 5′-TGCCATCCGTCCTTGAGGTAGAC
-3′); TRPV2 (sense: 5′-TCACCGCTGTTGCCTACCATCA 3′;
antisense: 5′-AGGGCTACAGCGAAGCCGAAAA-3′); TRPC1
(sense: 5′-ACCTTCCATTCGTTCATTGG-3′; antisense: 5′-TG
GTGAGGGAATGATGTTGA-3′; and GAPDH (sense: 5′-TG
CACCACCAACTGCTTAGC-3′, antisense: 5′-GGCATGGACT
GTGGTCATGAG-3′). Ampliﬁcation was performed with
150 ng of cDNA, 20 ng of genomic DNA, 200 nM primers
and 2.5 units of Taq polymerase (Thermo-Fisher Scientiﬁc,
Villebon-sur-Yvette, France). The protocol consisted of dena-
turation at 94 °C for 5min; 40 cycles of 94 °C for 40 s, 60 °C for
40 s and extension at 72 °C for 1min; and a ﬁnal cycle at 72 °C
for 10min. For quantitative real-time PCR (qRT-PCR), Taq-
Man gene expression assay FAM/MGB probes (Hs 00901640_
m1-human TRPV2, Hs 00608195_m1 human TRPC1, and Hs
99999905_m1 human GAPDH) were obtained from Applied
Biosystems (Foster City, CA, USA). For CD5, speciﬁc primers
(sense: 5′-TCGGACGGCTCAGCTGGTATGAC-3′; antisense:
5′-TGCCATCCGTCCTTGAGGTAGAC-3′) were used at
500 nM plus 1× SYBR Green PCR Master Mix (Applied
Biosystems). mRNA levels were normalized to GAPDH, and
cycle thresholds were compared using the 2−ΔΔct method.
Gene ontology and the analysis of biological pathways
The FatiGO web-interface was employed to carry out data mining
using the Gene Ontology database (www.geneontology.org).
The signaling pathways were grouped according to functional
classes and pathways.
Statistical analyses
Differences between the cell lines were analyzed using Student’s
t-test and/or the Mann–Whitney U-test when appropriate.
P-values were determined using the GraphPad Prism Version
6.0 (San Diego, CA, USA) statistical software package, and
values less than 0.05 were considered signiﬁcant.
RESULTS
CD5 promotes constitutive activation of pErk1/2
Erk1/2 is a key signaling molecule in normal and B-CLL cell
survival and IL-10 production.13 An association between CD5
expression, constitutive Erk1/2 phosphorylation (pErk1/2) and
IL-10 production has been suggested.22 To assess this associa-
tion directly, we compared pErk1/2 levels in untransfected
and CD5-transfected Jok-1 cells. The results revealed that Jok-1
transfection with either the membrane isoform of CD5
(Jok-E1A) or the cytoplasmic isoform (Jok-E1B) markedly
enhanced constitutive pErk1/2 (Figure 1a). To explore the
molecular mechanism(s) underpinning the increase in pErk1/2
induced by CD5, we transfected Jok-1 cells with CD5 mutants
(Figure 1b). Transfection with CD5 lacking the extracellular-
transmembrane domains S398Mstart or S415Mstart or with
mutations in the intracellular domain (422AS423→ 422VD423
or 459SDS461→ 459VDG461) did not affect constitutive pErk1/2
and IL-10 production (Figures 1c and d). However, transfec-
tion with CD5 mutated in the intracellular domain
(428EYS430→ 428AAA430) reduced pErk1/2 and IL-10 produc-
tion to levels similar to those observed in untransfected Jok-1
cells (IL-10: 99.7± 5.5 pg/ml with native CD5 versus
19.3± 5.5 pg/ml in 428AAA430 CD5, Po0.05). This indicates
that the 428EYS430 motif, which encompasses the Src kinase-
docking site Y429, is critical for constitutive pErk1/2 and IL-10
production, irrespective of the subcellular location of CD5.
Constitutive Erk1/2 phosphorylation is independent of BCR
engagement
Canonical BCR-dependent Erk1/2 phosphorylation involves
the activation of Syk/Btk/PLCγ2 pathway, which is regulated
by two phosphatases, SHP1 and SHIP.30 To determine if
constitutive Erk1/2 phosphorylation in Jok-E1A/E1B cells
occurs as the result of an association between CD5 and the
BCR, we determined the phosphorylation status of Syk,
Btk, PLCγ2, SHP1 and SHIP in non-activated Jok-1 and
Jok-E1A/E1B cells. The results showed that pSyk, pBtk,
pPLCγ2 and pSHIP phosphorylation status not different in
Jok-1 cells compared with Jok-E1A/E1B cells (Figure 2a).
However, the level of pSHP1 phosphorylation was higher in
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Jok-E1A/E1B cells compared with Jok-1 cells, as previously
reported in CD5+ CLL B cells.18
To further test the hypothesis that constitutive pErk1/2 is
BCR-independent in CD5+ B cells, we carried out immuno-
precipitation experiments with anti-CD5 mAb (clone UCHT2)
and WB (Figure 2b). These experiments conﬁrmed that CD5
was not associated with the BCR complex (CD79a) when the
BCR was not engaged, while engagement with F(ab’)2 anti-IgM
resulted in the co-precipitation of CD79a with CD5. In
contrast, SHP1 co-precipitated with CD5 in Jok-E1A cells only
when the BCR was not engaged. These data are consistent with
our previous ﬁndings showing that CD79a associates with CD5
in B-CLL only after BCR engagement.31
To rule out the possibility that our ﬁndings were attributable
to defective BCR-mediated signaling in Jok-1 cells, the kinetics
of PLCγ2 and Erk1/2 phosphorylation were studied before and
after BCR engagement with the F(ab’)2 anti-IgM. As shown in
Figure 2c, the level of pPLCγ2 phosphorylation was similar in
all three cells lines before BCR engagement. PLCγ2 phosphor-
ylation increased after 5 min and continued until 30min post
BCR engagement, conﬁrming that BCR-mediated signaling is
functional in Jok-1 cells (Figure 2c). Phosphorylation of Erk1/2
in the three cell lines with BCR engagement was highest at
2.5min and declined thereafter (Figure 2d). Notably, increased
pErk1/2 levels were merely additive and proportional to the
baseline in the three cell lines. The data, therefore, indicate that
enhanced Erk1/2 phosphorylation by CD5 occurs independent
of the BCR and through different pathways.
CD5 expression induces multiple signaling pathways
To identify the signaling pathway(s) through which CD5
enhances constitutive pErk1/2, the effects of plasma membrane
and intracellular CD5 isoform expression on intracellular
signaling were assessed through kinome array analyses.
Signiﬁcant changes (Po0.05) in the phosphorylation of 1024
substrates of all known kinases were reported when the
increase was ⩾ 2-fold higher, while decreases were reported
when levels were 0.5-fold or less. The phosphorylation of 154
substrates was increased, and the phosphorylation of 29
substrates was decreased in Jok-E1A/E1B cells compared with
Jok-1 cells (key substrates are presented in Table 2). Analyses of
kinases and the biological pathways reﬂected in these changes
performed using FatiGO revealed that at least two pathways,
one driving Ras/Erk, calmodulin and PKC through Ca2+
activation and another driving the PI3K/Akt/mTOR pathway,
were either activated or activation was enhanced in the
presence of CD5 (summarized in Figure 3a). Activation of
PI3K/Akt/mTOR was further studied using WB (Figure 3b),
which conﬁrmed an increase in the constitutive phosphoryla-
tion of Akt and S6K in Jok-E1A/E1B cells compared with Jok-1
cells. Activation of the PI3K/Akt/mTOR pathway was related to
the association between CD5 and the p85 unit of PI3K, as
Figure 1 Constitutive Erk1/2 activation and IL-10 production in CD5-expressing B cells is dependent on the phosphorylation of Y429 in
the CD5 molecule. (a) The upper panel depicts WB analysis of phosphorylated Erk1/2 (pErk1/2) in untransfected Jok-1 cells and Jok-1
cells transfected with membrane (E1A-CD5) or cytoplasmic (E1B-CD5) CD5. The lower panel shows the total levels of Erk1/2. (b) Cartoons
representing full-length CD5 and the mutants generated in this study to identify sites in CD5 involved in Erk1/2 activation. CD5 has three
extracellular domains (1–3), a transmembrane (Tm) region and a cytoplasmic domain. Truncated CD5 molecules (S398Mstart and
S415Mstart) are named according to their start codons. (c) WB of constitutive Erk1/2 phosphorylation in untransfected Jok-1 cells (labeled c)
and cells transfected with native CD5 (1) or with the mutants generated as shown in the cartoons. (d) ELISA results for IL-10 levels
produced by the corresponding cells in c. The cells were cultured for 48 h. The data in c and d represent three independent experiments.
Statistical analyses were performed by calculating the Mann–Whitney U-test for IL-10 production. * indicates Po0.05 for signiﬁcant
differences in IL-10 production between Jok-1 cells transfected with 428AAA430 compared with the full-length CD5 molecule. Erk1/2,
extracellular signal-regulated kinases 1/2; ELISA, enzyme-linked immunosorbent assay; pErk1/2; phosphorylated Erk1/2; WB, western
blotting.
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established by immunoprecipitation with a mAb for CD5
(Figure 3c). Moreover, we established a link between CD5
and Lyn, as well as with the U3-ubiquitin ligase c-Cbl and the
kinase Vav1, as previously described in thymocytes.32
Comparing the effects of membrane versus cytoplasmic CD5
revealed not only the overlaps between the effects of the two
isoforms on kinase activation but also the differences in how
they impact signaling (Table 3). Both isoforms activated the
Ca2+-dependent Ras/Erk, PKC and PI3K/Akt/mTOR pathways.
CD5 expression impacts the Ca2+ pathway
Kinome analysis indicated that constitutive Erk1/2 phosphor-
ylation in CD5+ B cells is dependent on the Ca2+ pathway. To
verify this observation, we carried out single-cell video micro-
scopy and observed an elevated resting initial ﬂuorescence
ratio, suggesting an increase in the basal level of iCa2+ in Jok-
E1A cells compared with Jok-1 cells (340/360: 1.155± 0.009,
n= 1723, in Jok-E1A cells versus 1.067± 0.007, n= 1623, in
Jok-1 cells; Po0.001, Figures 4a and b). Jok-E1B cells were
excluded from this analysis because these cells constitutively
express the ﬂuorescent marker GFP. On the basis of the
observation that such effects could be reversed when Ca2+ was
depleted from the media in the absence of stimulation
(Figure 4b), we next assessed whether this increase could be
the result of elevated constitutive extracellular Ca2+ entry. To
test this, we carried out Ca2+ repletion experiments followed by
the addition of the non-selective plasma membrane Ca2+
channel blocker La3+. The results revealed that with Ca2+
repletion, iCa2+ increased in resting Jok-E1A cells (ΔF/F0:
0.16± 0.01 Jok-E1A cells versus 0.08± 0.01 Jok-1 cells,
Po0.001) (Figures 4c and d). In addition, the experiments
indicated that this effect can be reversed with La3+. These
Figure 2 Constitutive Erk1/2 phosphorylation in CD5-expressing B cells is BCR-independent. (a) WB analysis of Syk, BTK, PLCγ2, SHP1
and SHIP phosphorylation in Jok-1, Jok-E1A and Jok-E1B cells. (b) Anti-CD5 immunoprecipitation (IP: αCD5) followed by WB of Jok-E1A
cells to assess the association between CD5 and the BCR complex in resting and F(ab’)2 anti-human IgM (α-IgM)-stimulated Jok-E1A
cells. The left panel shows CD5, CD79a and SHP1 in Jok-E1A cell lysate (WB), tested as controls. The panel on the right depicts the
association between CD5 and CD79a after α-IgM stimulation following IP with anti-CD5 mAb (c) WB to reveal the kinetics of PLCγ2
phosphorylation in unstimulated Jok-1, Jok-E1A and Jok-E1B cells or cells stimulated with anti-IgM. The upper three panels depict the
kinetics of PLCγ2 activation from 0 to 10 min after BCR engagement with the anti-IgM. The blots indicate pPLCγ2; the middle band is
total PLCγ2 protein (PLCγ2), and the lower band is β-actin protein. The bottom three panels depict the levels of pPLCγ2 at time points 0,
20 and 30 min after BCR engagement with anti-IgM. (d) Analysis of the kinetics of pErk1/2 following BCR engagement arranged as in c.
The two graph panels to the right of the western blots represent semi-quantiﬁcation data for the levels of pPLCγ2 as in c and pErk1/2 in d
for the signaling molecules, represented as the ratio of band intensity for the phosphorylated proteins to the band intensity of the total
protein. BCR, B-cell receptor; BTK, Bruton’s tyrosine kinase; Erk1/2, extracellular signal-regulated kinases 1/2; IP, immunoprecipitation;
pPLCγ2, phosphorylated PLCγ2; SHIP, SH2-containing inositol phosphatase; SHP1; SH2 domain-containing protein tyrosine phosphatase-1;
WB, western blotting.
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ﬁndings conﬁrm the hypothesis that the effect of CD5 is
dependent on membrane Ca2+ channels.
We next carried out inhibition experiments to conﬁrm the
dependence of Erk1/2 phosphorylation by CD5 on Ca2+ using
PD98059 and La3+. PD98059 inhibits MEK/Erk activation,
while La3+ inhibits extracellular Ca2+ entry. In addition, as
increases in iCa2+ and Ca2+ inﬂux in lymphocytes may involve
the PI3K/Akt/mTOR pathway, which is activated in resting
CD5+ B cells as shown in this study, pErk1/2 activation was
evaluated in the presence of LY294002, which inhibits PI3K,
and rapamycin, which inhibits mTor.33,34 Interestingly,
LY294002 and rapamycin had no effects on pErk1/2 in contrast
to PD98059 and La3+ (Figure 5a). To conﬁrm this observation, we
assessed whether the phosphorylation of STAT1/3 S727 also
occurred independent of the PI3K/mTor pathway.35 Again,
PD98059 and La3+, but not LY294002 or rapamycin, inhibited
pSTAT1/3 S727 in Jok-E1A/E1B cells. Furthermore, PD98059 and
La3+ also inhibited IL-10 production (Figure 5b). These data,
therefore, indicate that iCa2+ and constitutive Erk1/2-STAT1/3
phosphorylation increase when CD5 is expressed in B cells,
bypassing the PI3K/Akt/mTOR pathway, and this may result from
the transient upregulation of Ca2+ membrane channel(s).
Table 2 Kinase activation proﬁles and change in their activity in Jok-E1A and Jok-E1B relative to untransfected Jok-1 cells
Peptide with phosphorylation site Protein substrate Kinase Function E1A/Ctrl E1B/Ctrl Change
FIGEHYVHVNA HGFR/MET (Y1349) Abl, autoP TK receptor 4.7 3.5 Up
PESIHSFIGDG MTOR (S2481) Akt, autoP Akt/mTOR 2.7 2.2 Up
EVPRRSGLSAG MBD3 (S24 S26) Aurora A 4.4 3.4 Up
PGMKIYIDPFT EPHB1 (Y594) autoP TK receptor 4 3.9 Up
DIKSDSILLTS CDC42/PAK5 (S573) autoP, Ca2+ Prot Kinase 6.1 5 Up
CEEEFSDSEEE HDAC1 (S421 S423) autoP, CK2 Cell cycle, DNA repair 2 2.4 Up
ETPAISPSKRA dUTPase/DUT (S99) CDC2 Enzyme 5.6 5.2 Up
GDAAETPPRPR MEK1/MAP2K1 (T286) CDK1 MAPK/Erk 5.3 4.3 Up
DPWGGSPAKPS EPN1 (S357) CDK1 Vesicle formation 7.5 9 Up
SASPYTPEHAA TP73 (T86) CDK1/2, CDC2, autoP Cell cycle 5.6 6.1 Up
LSRMGSLRAPV E2F1 (S364) CHK2 TF 3.3 3.2 Up
PELARYLNRNY HRS/HGS (Y329) EGFR/MET Vesicle formation 4 4.9 Up
DYDDMSPRRGP HNRNPK (S284) Erk RNA binding 3.5 2.7 Up
AEVLPSPRGQR TOP2A (S1213) Erk1, CDK1 Cell cycle 3.7 3.5 Up
GPHRSTPESRA PSEN1 (S353 S357) GSK3B MAPK/Erk 4.1 4.2 Up
RSGLCSPSYVA MYC (S71) MAPK/JNK TF 2.3 2.3 Up
EKPRLSFADRA PKC theta (S676) nd PKC 4.9 4.1 Up
ALRRESQGSLN RGS14 (S260) PKA GTPase 9.8 11 Up
SAWPGTLRSGM HSPB8 (T63) PKC Small HSP 3.5 3.2 Up
TTCVDTRWRYM HIR/KCNJ4 (T53) PKC K receptor 3.1 2.8 Up
KSFTRSTVDTM CD88/C5AR1 (S334 S338) PKC G protein 3.8 3.6 Up
AGIQTSFRTGN DDX5 (S557) PKC, autoP RNA binding 2.7 2.9 Up
LLREASARDRQ TRPV1 (S801) PKCalpha, Ca2+ Ca receptor 3 2.8 Up
EHRKSSKPIME HES1 (S37-38) PKCalpha, Ca2+ TR 6.3 5.2 Up
ESLESTRRILG SNAP23 (S23 T24) PKCalpha, Ca2+ Vesicle 2.5 2.8 Up
EGKHLYTLDGG Rack1/GNB2L1 (Y228) Src kinase G protein 3.4 2.2 Up
SRLSAYPALEG CD5 (Y465) Src kinase PI3K 2.8 2.9 Up
EVERTYLKTKS GRIN2A (Y1105) Src kinase (Fyn) Ca receptor 4.1 3.1 Up
PCTTIYVAATE CD150/SLAM (Y307) Src kinase (Fyn) ITAM receptor 2.7 2 Up
EEGEGYEEPDS CD19 (Y409) Src kinase (lyn) ITAM receptor 2.3 2.5 Up
GTDLEYLKKVR OGT (Y989) Src kinase, INSR Enzyme 2.5 2.3 Up
GSPSVRCSSMS SMAD2 (S464 S465 S467) TGFBR, BMPR1 TF 3.8 4.7 Up
FMRRTSLGTEQ PTGER4 (S222) unknown G protein 5 5 Up
LDRFLSLEPVK CCND1 (S90) unknown Cell cycle 2.2 4 Up
HSLPFSLPSQM CBL (S623) unknown TK regulation 2.9 2.8 Up
TDGNRSSHSRL BID (S64 S65) unknown TF 2.4 2.3 Up
ASKMDTCSSNL F2R/PAR1 (S406) unknown G protein 0.3 0.5 Down
Abbreviations: autoP, autophosphorylated; CK2, casein kinase 2; Ctrl, control, refers to activity of the kinase in the untransfected Jok-1 cells; RTK, receptor tyrosine
kinase; TF, transcription factor; TK, tyrosine kinase; TR, transcription repressor.
The table lists peptide substrates whose phosphorylation status is different in Jok-1 cells transfected with the E1A or E1B isoforms of CD5, corresponding protein
substrates, kinases whose activity is altered and the ratio of activity of the kinase in the transfected cells compared with untransfected Jok-1 cells (according to
phosphositeplus database at http://www.phosphosite.org). Ratio: refers to the ratio of activity of the kinase in Jok-E1A/E1B cells compared with Jok-1 cells. The analyses
were carried out in triplicates for each cell line and the analysis repeated on two separate occasions. Differences were analyzed using student’s t-test. Po0.05 are
considered signiﬁcant and shown in the table. Change: indicates whether activity of the kinase in question was upregulated (Up), or downregulated (Down).
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CD5 expression alters the transcriptome of B lymphocytes
To provide further insight into the impact of CD5 on B cell
biology, we analyzed the transcriptome of the Jok-E1A
and Jok-E1B cell lines compared with the Jok-1 cell line
using a whole-human genome oligonucleotide microarray.
The analyses revealed that the expression levels of 621
unique genes were altered in Jok-E1A cells compared with
Jok-1 cells. Speciﬁcally, the expression of 502 (80.8%) genes
increased by 41.5-fold in CD5-E1A cells compared with
Jok-1 cells, while the expression of 119 (19.1%) genes
decreased by 41.5-fold in CD5-E1A cells compared with
Jok-1 cells. These results reveal the similarities between
some of the altered genes and those identiﬁed in a previous
study in Daudi B cells transfected with CD5 (Supplementary
Data). Thus, among those genes whose expression was
altered 42-fold, the expression of 45 genes was found to
be upregulated and seven were downregulated in both cell
lines. Some of the genes demonstrating altered expression
were genes encoding cytokines and chemokines (IL-10,
IL2RG and CCL3), signaling molecules (MKNK2 and
RGS1), apoptosis inhibitors (Bcl-2), transcription factors
(NF-KB2, Spi-C) and cell surface receptors (CD83, CD74,
CD54/ICAM1 and CD69).10 With the exception of 4 genes
(TRIM68, FRDM6, DYNLRB1 and FLJ11710), no differences
were observed between Jok-E1A and Jok-E1B cells.
Analysis of alterations in Ca2+-permeable channel expression
revealed upregulation of genes encoding the cationic channel
TRPV2 and TRPC1 in both Jok-E1A and Jok-E1B cells
Figure 3 Key signaling pathways affected by CD5 expression. (a) A cartoon representing the major kinases and signaling pathways whose
activities are affected by CD5 expression in Jok-1 B cells. Only the major kinases and signaling pathways are shown based on the kinome
array analysis and WB in the current study and data from the literature. (b) WB showing phosphorylation (top) and total protein levels
(bottom) of Akt and S6K in Jok-1, Jok-E1A and Jok-E1B cells. (c) Immunoprecipitation with anti-CD5 mAb in Jok-E1A cells reveals that
CD5 associates with Lyn, the p85 regulatory unit of PI3K, c-Cbl and Vav1. Representative of three independent experiments. ITAM,
immune receptor tyrosine-based activation motifs; TK, tyrosine kinase; WB, western blotting.
Table 3 Altered phosphorylation of kinase substrates by CD5
expression in Jok-1 B cells
Kinase CD5-E1A CD5-E1B
Up Down Up Down
PI-3K/Akt/mTOR 6 0 3 0
CaMkII 4 0 1 0
Cell cycle (CDK, CDC) 12 0 15 0
CK1/CK2 2 4 4 1
GSK3B 2 0 5 0
NF-κB 1 0 1 0
Jak/STAT 1 0 0 0
Ras-Erk 6 0 9 1
PKA 9 0 11 0
PKC 11 0 11 3
Src kinases 9 0 12 0
This table lists the number of target peptide substrates whose phosphorylation
status is upregulated (Up) or down-regulated (Down) in Jok-E1A and Jok-E1B
cells when compared with untransfected Jok-1 cells. The analysis was carried out
as described in Table 2 legend and is drawn on data summarized in the
same Table.
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compared with Jok-1 cells. Upregulation of both the TRPV2
and TRPC1 genes was conﬁrmed using RT-PCR in Jok-E1A/
E1B cells (Figure 6a).
CD5 drives TRPC1 expression and IL-10 production in
pErk1/2-positive B-CLL cells
To verify that CD5 drives IL-10 production through the
upregulation of TRPC1 and/or TRPV2, B cells from 26 patients
with CLL were segregated into two groups based on the
phosphorylation status of pErk1/2 as determined using WB
(Figure 6, and data not shown). As expected, pErk1/2 activa-
tion was associated with IL-10 production (Po0.01) in B-CLL
cells (Figure 6c). TRPV2 was detectable at low levels in B cells
from some CLL patients, but no differences were observed
between pErk1/2+ and pErk1/2− B-CLL in terms of TRPV2
transcripts as assessed using qRT-PCR (Figure 6c). In contrast,
TRPC1 transcripts were detectable at signiﬁcantly higher levels
in pErk1/2+ B-CLL patients compared with pErk1/2− B-CLL
patients (Po0.001). Notably TRPV2 and TRPC1 were not
detectable in B or T cells from healthy controls (data not
shown). Flow cytometry conﬁrmed that the TRPC1 protein
was expressed on B cells from pErk1/2+ CLL patients (MFI
TRPC1: 1.9± 1.3 in pErk1/2+ CLL patients versus 0.4± 0.1 in
pErk1/2− CLL patients, Po0.05) (Figure 6d). These data are
consistent with the expression of TRPC1 in the Jok-E1A cell
line (MFI: 5.9± 2.4 versus 0.4± 0.3 in Jok-1 cells, Po0.01).
The levels of Erk1/2 phosphorylation and TRPC1 expression
were independent of age, sex, CLL stage, disease progression,
CD38 expression or the cytogenetic status of the patients.
Finally, to conﬁrm that CD5 induces TRPC1 expression and
promotes IL-10 production, we employed siRNA targeting
CD5 and TRPC1 to transfect B-CLL cells from 3 pErk1/2+ and
3 pErk1/2− patients. After 2 days of culture, reductions in CD5
were evaluated at the mRNA level in CD5 and TRPC1 siRNA
transfected B-CLL cells from both groups. The expression of
TRPC1 was reduced with cd5-siRNA and TRPC1-siRNA in
pErk1/2+ B-CLL cells (Figure 6e). Both siRNAs resulted in the
inhibition of IL-10 production in pErk1/2+ B-CLL cells.
Collectively, these results indicate that in pErk1/2+ B-CLL cells,
CD5 promotes IL-10 production through a BCR-independent
Ca2+-dependent pathway that involves the non-selective Ca2+
channel protein TRPC1.
DISCUSSION
This study reveals that CD5 directly alters the biology of B cells
and induces IL-10 production. The molecular pathways
through which CD5 modulates B-cell biology appear to be
mediated through Erk1/2 activation in a Ca2+-dependent
pathway and involve the non-selective Ca2+ channel TRPC1.
Interestingly, the changes induced by CD5 are distinct from the
negative modulating effects that it exerts on BCR signaling.
Furthermore, the data reveal that pathways induced by CD5 in
B cells are similar to those activated in B-CLL, as induced CD5
expression replicates several characteristics of neoplastic B cells,
including constitutive basal Erk1/2 phosphorylation. This
Figure 4 CD5 expression modulates the Ca2+ pathway in B cells. (a) CD5 expression in Jok-E1A cells increases the basal levels of
intracellular Ca2+ (iCa2+) compared with Jok-1 cells. (b) Histograms representing basal levels of iCa2+ in Jok-1 and Jok-E1A cells.
The increase in basal iCa2+ in Jok-E1A cells is sensitive to extracellular Ca2+ depletion (no Ca2+), as can be noted in a and conﬁrmed in c.
Re-addition of extracellular Ca2+ to resting Jok-1 and Jok-E1A cells as shown in c reveals a high extracellular and constitutive Ca2+ inﬂux
in Jok-E1A cells. This inﬂux can be reversed in the presence of lanthanum (La3+); ratios are normalized to basal values (F0), indicated as
(ΔF/F0). The mean and s.e.m. of the ΔF/F0 values in c are from six independent experiments presented in histograms in d. *** indicates
Po0.001 values for the difference between the two cell lines, as determined using Student’s t-test.
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observation is consistent with previous studies13, as is the
ability of CD5 to activate STAT1/335 and IL-10 production;8
these are all features of neoplastic B-CLL cells. In addition,
CD5 expression resulted in the perturbation of Ca2+ home-
ostasis, leading to increased basal iCa2+.36
Consistent with our observation that the expression of CD5
induces biological changes in a manner that is distinct from its
role in modulating effects on BCR-mediated signaling, we
observed that CD5 exerts a distinct effect on Ca2+ mobilization
in both settings.31 The characteristics noted in CD5+ B cells are
similar to those observed in anergic37,38 B cells and CD5+
transitional B cells.39–41 This ‘anergic signature’ was previously
shown to be a characteristic feature of B-CLL cells.42 Interest-
ingly, the anergic phenotype of B cells was shown to be
reversed in hen egg lysozyme (HEL) transgenic mice when the
mice were CD5-deﬁcient.24
The current study also provides in-depth analysis of the
pathways leading to the constitutive activation of Erk1/2 and
IL-10 production in B-CLL cells. Thus, the study shows that a
Ca2+ inﬂux-dependent pathway is involved in constitutive
Erk1/2 phosphorylation and IL-10 production. Unlike conven-
tional CD5− B2 cells in which Erk1/2 phosphorylation is
mediated through Syk/BTK/PLCγ2 and PI3K activation follow-
ing BCR engagement,43 constitutive Erk1/2 phosphorylation by
CD5 occurs independent of this pathway. This was demon-
strated through the ﬁnding that Syk, BTK and PLCγ2 were not
activated in unstimulated CD5+ B cells and that the inhibition
of PI3K by LY294002 was ineffective at suppressing constitutive
Erk1/2 phosphorylation, which stands in contrast to the
effectiveness of the non-selective Ca2+ channel blocker La3+.
The newly identiﬁed pathway is compatible with the observations
that inhibition of Erk1/2 phosphorylation in B-CLL cells does
not occur immediately after BTK inhibition44 and that Erk1/2
phosphorylation in leukemic B cells in patients with CLL failed
to mobilize Ca2+ upon BCR crosslinking.13,42
Figure 5 CD5 promotes the phosphorylation of Erk1/2 and STAT1/STAT3 S727 and IL-10 production, which are dependent on
extracellular Ca2+ entry. (a) Analysis of constitutive Erk1/2 phosphorylation, STAT1 S727 phosphorylation, STAT3 S727 phosphorylation
and (b) IL-10 production in Jok-1, Jok-E1A and Jok-E1B cells after 48 h of culture in the presence of PD98059 (at 50 μM for WB and at
100 μM for IL-10 production), lanthanum (La3+), rapamycin (Rapa) or Ly294002 (Ly29). PD98059 inhibits MEK1 and 2; La3+ blocks
extracellular Ca2+ entry; rapamycin inhibits PI3-K/mTOR; and Ly294002 inhibits PI3K/Akt. Cells cultured without inhibitors are used as
controls and marked ‘c’. IL-10 levels produced by cells cultured either alone or with the indicated inhibitors were determined using ELISA,
and IL-10 levels are expressed as the percentage of basal values; % reduction is presented as the mean and s.e.m. for three independent
experiments. The basal value of IL-10 was 32±6.9 pg/ml in Jok-1 cells and 105±8.7 pg/ml for CD5-transfected cells. * indicates
Po0.05 for IL-10 production levels in the presence of a given inhibitor compared with cultured cells without inhibitors as determined by
the Mann–Whitney U-test. ELISA, enzyme-linked immunosorbent assay. WB, western blotting.
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Given that CD5+ B cells in healthy individuals, patients with
autoimmune diseases such as systemic lupus erythematosus,
and also patients with CLL cells express both isoforms of
CD5,45 albeit at different levels, we studied whether these two
isoforms differentially impact intracellular signaling. The results
indicated that there were no major differences in terms of the
effects that the two isoforms exert on intracellular signaling in
B cells with the exception that E1B-CD5 cells downregulated
the level of CD5 expression on the membrane.12,45 These
results indicate that the 428EYS430 motif is functional in both
isoforms, which is in agreement with previous studies showing
that the CD5 Y429 is constitutively phosphorylated in B-CLL
cells,10 most likely by Lyn,18 and that this phosphorylation has
a positive effect on transcription but a negative effect on BCR-
mediated signaling.
The mechanisms through which CD5 exerts a dual role in
modulating B-cell signaling and biology, however, remain
unclear. This is in part due to the capacity of CD5 to activate
a large array of kinases and phosphatases, as shown in our
current study. Consistent with the inhibitory effects of CD5 on
BCR-mediated signaling, we observed that CD5 associates with
SHP1 and c-Cbl in resting cells but with CD79a following BCR
engagement. The positive effect of CD5 on gene transcription,
however, appears to be attributable to the recruitment of key
Figure 6 TRPC1 regulates extracellular Ca2+ entry by CD5 in Jok-1 B cells and B cells from Erk1/2+ B-CLL patients. (a) Transcripts of
CD5, TRPV2, TRPC1 and GAPDH in Jok-1, Jok-E1A and Jok-E1B B cells as determined using RT-PCR. (b) B-CLL patients were divided
into two groups based on the phosphorylation status of the Erk1/2 protein as assessed using WB. # indicates B cells from CLL patients
positive for constitutively phosphorylated Erk1/2. (c) Levels of IL-10 (n=26 patients), TRPC1 (n=26) and TRPV2 (n=12) transcripts
relative to GAPDH mRNA as determined using real-time PCR in B cells from pErk1/2+ and pErk1/2− B-CLL patients. ** indicates Po0.01
and *** indicates Po0.001 for the relative levels of IL-10 and TRPC1 transcripts between pErk1/2+ and pErk1/2− B-CLL patients,
respectively, as determined using Student’s t-test. (d) Representative FACS plot of extracellular TRPC1 protein expression (black
histograms) in CLL#2 (pErk1/2−), CLL#15 (pErk1/2+), Jok-1, and Jok-E1A cells. MFI, indicated for each cell; isotype controls are
presented as gray histograms. (e) Histograms depicting levels of TRPC1, CD5 and IL-10 transcripts in B cells from pErk1/2+ (black
histograms) and pErk1/2− (white histograms) B-CLL patients following transfection with c-siRNA, CD5-siRNA and TRPC1-siRNA. The top
two histograms depict relative levels of CD5 (left) and TRPC1 (right) transcripts relative to GAPDH mRNA. The lower two histograms
represent relative levels of IL-10 transcripts relative to GAPDH in pErk1/2+ (left) and pErk1/2− patients (right). B cells from three pErk1/2+
and three pErk1/2− B-CLL patients were studied in these experiments. * indicates Po0.05 for the levels of CD5, TRPC1 and IL-10
transcripts observed when using siRNA targeting CD5 or TRPC1 compared with c-siRNA. Statistical analyses were carried out using
Student’s t-test. CLL, chronic lymphocytic leukemia; c-siRNA, control siRNA; MFI; mean ﬂuorescence intensity; RT-PCR, PCR with reverse
transcription; WB, western blotting.
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kinases, including Lyn, the p85 unit of PI3K and Vav1. The
molecular mechanism(s) through which CD5 modulates Ca2+
homeostasis and the role of TRPC1 in the process have yet to
be deﬁned.
The expression of TRP channels has been associated with
cancer, and, in particular, TRPC1 overexpression was described
in a transformed CD5+ chicken DT-40 cell line and in human
B-lymphoblast cell lines.46,47 In DT-40 cells, TRPC1 was linked
to increases in intracellular Ca2+ and the activation of
NFAT2,46 a signaling cascade that leads to cytokine/chemokine
production in B-CLL cells. Interestingly, mice deﬁcient in
TRPC1 have defective B cell functions, similar to those
observed in NFAT2-deﬁcient mice.48 Consequently, TRPC1
upregulation in CD5+ B cells may be an important mechanism
that promotes B-CLL cell survival.
CONCLUSIONS
This study provides molecular evidence that CD5 expression
alters B cell biology, including the constitutive activation of key
signaling pathways leading to IL-10 production. Pathways and
transcription factors activated by CD5 include those involved
in regulating B-cell survival, proliferation, cytokine/chemokine
production and transformation. The ﬁndings reported in this
study facilitate a better understanding of the biology and
regulatory properties of CD5+ B cells in health and in diseases,
including in patients with B-CLL, and how CD5 may poten-
tially contribute to B-cell abnormalities. These ﬁndings may aid
in the design of new treatment strategies, particularly for CLL
patients identiﬁed as refractory to currently available treat-
ments. Such treatment strategies could involve the use of
monoclonal antibodies targeting membrane proteins relevant
to B-CLL cell transformation, such as TRPC1 or CD5, in the
form of mono or combination therapies.28 Alternatively,
signaling pathways mediated by CD5 and involved in B-CLL
cell transformation may be modulated. For example, high basal
Ca2+ levels36 or upstream kinases could be targeted, a strategy
that has successfully been employed to treat patients with
autoimmune diseases.49
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
This study was supported by a grant from Arthritis Research-UK to
RAM and by grants from the “Cancéropole Grand Ouest”, the
“Région Bretagne” and the “Ligue contre le cancer” to YR. We thank
Catherine Riou and Professor Valérie Ugo (Brest) for the clinical
material and Ms Simone Forest and Geneviève Michel for helping with
typing the manuscript.
1 Berland R, Wortis HH. Origins and functions of B-1 cells with notes on
the role of CD5. Annu Rev Immunol 2002; 20: 253–300.
2 Hardy RR, Hayakawa K, K. CD5B cells, a fetal B cell lineage. Adv
Immunol 1994; 55: 297–339.
3 Hayakawa K, Formica AM, Colombo MJ, Ichikawa D, Shinton SA,
Brill-Dashoff J et al. B cells generated by B-1 development can
progress to chronic lymphocytic leukemia. Ann NY Acad Sci 2015;
1362: 250–255.
4 Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul
AH. Human CD5 promotes B-cell survival through stimulation of
autocrine IL-10 production. Blood 2002; 100: 4537–4543.
5 Burdin N, Rousset F, Banchereau J. B-cell-derived IL-10: production
and function. Methods 1997; 11: 98–111.
6 Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10
and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:
683–765.
7 Defrance T, Vanbervliet B, Brière F, Durand I, Rousset F, Banchereau J.
Interleukin 10 and transforming growth factor beta cooperate to
induce anti-CD40-activated naive human B cells to secrete
immunoglobulin A. J Exp Med 1992; 175: 671–682.
8 Kitabayashi A, Hirokawa M, Miura AB. The role of interleukin-10
(IL-10) in chronic B-lymphocytic leukemia: IL-10 prevents
leukemic cells from apoptotic cell death. Int J Hematol 1995; 62:
99–106.
9 Fayad L, Keating MJ, Reuben JM, O’Brien S, Lee BN, Lerner S et al.
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leuke-
mia: correlation with phenotypic characteristics and outcome. Blood
2001; 97: 256–263.
10 Gary-Gouy H, Sainz-Perez A, Marteau JB, Marfaing-Koka A, Delic J,
Merle-Beral H et al. Natural phosphorylation of CD5 in chronic
lymphocytic leukemia B cells and analysis of CD5-regulated genes in
a B cell line suggest a role for CD5 in malignant phenotype. J Immunol
2007; 179: 4335–4344.
11 Garaud S, Le Dantec C, de Mendoza AR, Mageed RA, Youinou P,
Renaudineau Y. IL-10 production by B cells expressing CD5
with the alternative exon 1B. Ann NY Acad Sci 2009; 1173:
280–285.
12 Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers JO et al.
CD5 promotes IL-10 production in chronic lymphocytic leukemia B
cells through STAT3 and NFAT2 activation. J Immunol 2011; 186:
4835–4844.
13 Apollonio B, Scielzo C, Bertilaccio MT, Ten Hacken E, Scarfò L,
Ranghetti P et al. Targeting B-cell anergy in chronic lymphocytic
leukemia. Blood 2013; 121: 3879–3888.
14 Li P, Grgurevic S, Liu Z, Harris D, Rozovski U, Calin GA et al.
Signal transducer and activator of transcription-3 induces
MicroRNA-155 expression in chronic lymphocytic leukemia. PLoS
One 2013; 8: e64678.
15 Sarrias MR, Grønlund J, Padilla O, Madsen J, Holmskov U, Lozano F.
The scavenger receptor cysteine-rich (SRCR) domain: an ancient and
highly conserved protein module of the innate immune system. Crit
Rev Immunol 2004; 24: 1–37.
16 Gary-Gouy H, Bruhns P, Schmitt C, Dalloul A, Daëron M, Bismuth G.
The pseudo-immunoreceptor tyrosine-based activation motif of CD5
mediates its inhibitory action on B-cell receptor signaling. J Biol Chem
2000; 275: 548–556.
17 Gary-Gouy H, Lang V, Sarun S, Boumsell L, Bismuth G. In vivo
association of CD5 with tyrosine-phosphorylated ZAP-70 and p21
phospho-zeta molecules in human CD3+ thymocytes. J Immunol
1997; 159: 3739–3747.
18 Tibaldi E, Brunati AM, Zonta F, Frezzato F, Gattazzo C, Zambello R
et al. Lyn-mediated SHP-1 recruitment to CD5 contributes to resis-
tance to apoptosis of B-cell chronic lymphocytic leukemia cells.
Leukemia 2011; 25: 1768–1781.
19 Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA,
Kanner SB. CD5 negatively regulates the T-cell antigen receptor
signal transduction pathway: involvement of SH2-containing phospho-
tyrosine phosphatase SHP-1. Mol Cell Biol 1999; 19: 2903–2912.
20 Bauch A, Campbell KS, Reth M. Interaction of the CD5 cytoplasmic
domain with the Ca2+/calmodulin-dependent kinase IIdelta. Eur J
Immunol 1998; 28: 2167–2177.
21 Raman C, Kuo A, Deshane J, Litchﬁeld DW, Kimberly RP. Regulation
of casein kinase 2 by direct interaction with cell surface receptor CD5.
J Biol Chem 1998; 273: 19183–19189.
22 Wong SC, Chew WK, Tan JE, Melendez AJ, Francis F, Lam KP.
Peritoneal CD5+ B-1 cells have signaling properties similar to tolerant
B cells. J Biol Chem 2002; 277: 30707–30715.
23 Gary-Gouy H, Harriague J, Dalloul A, Donnadieu E, Bismuth G.
CD5-negative regulation of B cell receptor signaling pathways
originates from tyrosine residue Y429 outside an immuno-
CD5 promotes MAPK/Erk activation and IL-10 production in B cells
S Garaud et al
12
Cellular & Molecular Immunology
receptor tyrosine-based inhibitory motif. J Immunol 2002; 168:
232–239.
24 Hippen KL, Tze LE, Behrens TW. CD5 maintains tolerance in anergic
B cells. J Exp Med 2000; 191: 883–890.
25 Parikh K, Poppema S, Peppelenbosch MP, Visser L. Extracellular
ligation-dependent CD45RB enzymatic activity negatively regulates
lipid raft signal transduction. Blood 2009; 113: 594–603.
26 Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES.
The 2008 WHO classiﬁcation of lymphoid neoplasms and beyond:
evolving concepts and practical applications. Blood 2011; 117:
5019–5032.
27 Gross HJ, Merling A, Moldenhauer G, Schwartz-Albiez R. Ecto-
sialyltransferase of human B lymphocytes reconstitutes differentiation
markers in the presence of exogenous CMP-N-acetyl neuraminic acid.
Blood 1996; 87: 5113–5126.
28 Loisel S, André PA, Golay J, Buchegger F, Kadouche J, Cérutti M et al.
Antitumour effects of single or combined monoclonal antibodies
directed against membrane antigens expressed by human B cells
leukaemia. Mol Cancer 2011; 10: 42.
29 Devauchelle-Pensec V, Cagnard N, Pers JO, Youinou P, Saraux A,
Chiocchia G. Gene expression proﬁle in the salivary glands of primary
Sjogren’s syndrome patients before and after treatment with rituximab.
Arthritis Rheum 2010; 62: 2262–2271.
30 Richards JD, Davé SH, Chou CH, Mamchak AA, DeFranco AL.
Inhibition of the MEK/ERK signaling pathway blocks a subset of B
cell responses to antigen. J Immunol 2001; 166: 3855–3864.
31 Nédellec S, Renaudineau Y, Bordron A, Berthou C, Porakishvili N,
Lydyard PM et al. B cell response to surface IgM cross-linking
identiﬁes different prognostic groups of B-chronic lymphocytic leuke-
mia patients. J Immunol 2005; 174: 3749–3756.
32 Roa NS, Ordoñez-Rueda D, Chávez-Rios JR, Raman C, García-Zepeda EA,
Lozano F et al. The carboxy-terminal region of CD5 is required for
c-CBL mediated TCR signaling downmodulation in thymocytes.
Biochem Biophys Res Commun 2013; 432: 52–59.
33 Buhl AM, Pleiman CM, Rickert RC, Cambier JC. Qualitative regulation
of B cell antigen receptor signaling by CD19: selective requirement for
PI3-kinase activation, inositol-1,4,5-trisphosphate production and Ca2
+ mobilization. J Exp Med 1997; 186: 1897–1910.
34 Chen J, Fang Y. A novel pathway regulating the mammalian target of
rapamycin (mTOR) signaling. Biochem Pharmacol 2002; 64:
1071–1077.
35 Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic
lymphocytic leukemia contain signal transducer and activator of
transcription (STAT) 1 and STAT3 constitutively phosphorylated on
serine residues. J Clin Invest 1997; 100: 3140–3148.
36 Muggen AF, Pillai SY, Kil LP, van Zelm MC, van Dongen JJ, Hendriks RW
et al. Basal Ca(2+) signaling is particularly increased in mutated chronic
lymphocytic leukemia. Leukemia 2015; 29: 321–328.
37 Healy JI, Dolmetsch RE, Timmerman LA, Cyster JG, Thomas ML,
Crabtree GR et al. Different nuclear signals are activated by the B cell
receptor during positive versus negative signaling. Immunity 1997; 6:
419–428.
38 Chumley MJ, Dal Porto JM, Cambier JC. The unique antigen receptor
signaling phenotype of B-1 cells is inﬂuenced by locale but induced by
antigen. J Immunol 2002; 169: 1735–1743.
39 Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE.
Identiﬁcation and characterization of circulating human transitional
B cells. Blood 2005; 105: 4390–4398.
40 Limnander A, Depeille P, Freedman TS, Liou J, Leitges M, Kurosaki T
et al. STIM1, PKC-delta and RasGRP set a threshold for proapoptotic
Erk signaling during B cell development. Nat Immunol 2011; 12:
425–433.
41 Limnander A, Zikherman J, Lau T, Leitges M, Weiss A, Roose JP.
Protein kinase Cdelta promotes transitional B cell-negative selection
and limits proximal B cell receptor signaling to enforce tolerance. Mol
Cell Biol 2014; 34: 1474–1485.
42 Muzio M, Apollonio B, Scielzo C, Frenquelli M, Vandoni I, Boussiotis V
et al. Constitutive activation of distinct BCR-signaling pathways in a
subset of CLL patients: a molecular signature of anergy. Blood 2008;
112: 188–195.
43 Kawauchi K, Ogasawara T, Yasuyama M. Activation of extra-
cellular signal-regulated kinase through B-cell antigen receptor in
B-cell chronic lymphocytic leukemia. Int J Hematol 2002; 75:
508–513.
44 Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M et al. BTK
inhibition targets in vivo CLL proliferation through its effects on B-cell
receptor signaling activity. Leukemia 2014; 28: 649–657.
45 Garaud S, Le Dantec C, Berthou C, Lydyard PM, Youinou P,
Renaudineau Y. Selection of the alternative exon 1 from the cd5 gene
down-regulates membrane level of the protein in B lymphocytes.
J Immunol 2008; 181: 2010–2018.
46 Mori Y, Wakamori M, Miyakawa T, Hermosura M, Hara Y, Nishida M
et al. Transient receptor potential 1 regulates capacitative Ca(2+) entry
and Ca(2+) release from endoplasmic reticulum in B lymphocytes.
J Exp Med 2002; 195: 673–681.
47 Roedding AS, Li PP, Warsh JJ. Characterization of the transient
receptor potential channels mediating lysophosphatidic acid-
stimulated calcium mobilization in B lymphoblasts. Life Sci 2006; 80:
89–97.
48 Yildirim E, Carey MA, Card JW, Dietrich A, Flake GP, Zhang Y et al.
Severely blunted allergen-induced pulmonary Th2 cell response and
lung hyperresponsiveness in type 1 transient receptor potential
channel-deﬁcient mice. Am J Physiol Lung Cell Mol Physiol 2012;
303: L539–L549.
49 O’Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted
therapy for RA and other autoimmune diseases. Nat Rev Rheumatol
2013; 9: 173–182.
Supplementary Information for this article can be found on the Cellular & Molecular Immunology website (http://www.nature.com/cmi)
CD5 promotes MAPK/Erk activation and IL-10 production in B cells
S Garaud et al
13
Cellular & Molecular Immunology
